
The use of immunohistochemistry (IHC) claims associated with Medicare melanoma diagnoses has increased significantly from 11% in 2000 to 51% in 2017, with substantial geographic variation in practice patterns, suggesting the need for research to optimize IHC use in melanoma diagnosis.


coremsg

With sparse guidance regarding best practices for IHC in melanoma diagnosis, more research is needed to optimize use of IHC in this setting, according to the authors.

Medicare IHC Claims With Melanoma Dxs Increased, Study Finds

increased-use-of-immunohistochemistry-in-medicare-patients-with-melanoma-diagnoses-raises-concerns-about-appropriate-utilization


Increased Use of Immunohistochemistry in Medicare Patients with Melanoma Diagnoses Raises Concerns about Appropriate Utilization
